Jim Cramer on Merck's Latest Quarterly Report: "I Actually Liked It"

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that he liked its quarter. He remarked:

“What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it. Small revenue miss, paired with an 11-cent earnings beat. Stock got hit, finishing the day down nearly 2% although it was a lot lower at one point.

Merck’s had a tough time over the past year, falling 45% from its highs in June of 2024 before recovering only modestly over the past couple weeks. Wall Street seems to be worried about that looming patent cliff for their blockbuster… best drug ever, Keytruda, which accounts for about half of the company’s sales. Doesn’t help that GARDASIL, their HPV vaccines, really struggled thanks to persistent weakness in China… While Merck’s made some excellent acquisitions to expand the drug pipeline, stock hasn’t gotten much credit for it. I think that’s wrong.”

Merck (NYSE:MRK) develops and sells pharmaceuticals for human and animal health, covering areas such as oncology, vaccines, virology, and livestock care. The company also holds multiple collaboration and licensing agreements to advance treatments across various medical conditions.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.